3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
5
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Hyperinsulinism
1
Colorectal Neoplasms
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled